Integrated BioPharma, Inc.
corporate_fare Company Profile
Integrated BioPharma, Inc. (OTC:INBP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for INBP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for INBP spans 10-Q, DEF 14A, 10-K, 8-K.
Recent high-impact activity:
- Integrated BioPharma Q1 Swings to $691K Net Loss as Sales Fall 21.9%
- Proxy Asks Shareholders to Approve 7.5M-Share Equity Plan at Nov 30 Meeting
- Integrated BioPharma FY2026: Sales Drop 19%, Gross Margin Collapses to 1.8%, Loan Covenant Breached
- Secures Extension of $4M Credit Line, Adds New $250k Equipment Facility
- INTEGRATED BIOPHARMA Reports Significant Quarterly and Nine-Month Losses Amidst Steep Revenue Decline
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 509 shares in INBP as of the October 30, 2026 settlement, unchanged from the prior period — about 1.0 days to cover at its recent average daily volume. On November 19, 2026, 99.5% of INBP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.